IMMUCELL CORP - 10-K Summary (Fiscal Year Ended Dec 31, 1995)
Business Context and Reporting Period
ImmuCell Corporation is a biotechnology company developing, manufacturing, and marketing milk-derived passive antibody products to prevent and treat gastrointestinal infections in humans and animals. The reporting period covers the fiscal year ended December 31, 1995. The Company's primary commercial product is FIRST DEFENSE{R}, a USDA-licensed capsule for preventing calf scours. The Company is also developing human therapeutic products (CRYPTOGAM{TM}, TRAVELGAM{TM}, DIFFGAM{TM}) and diagnostic technologies.
Key Financial Metrics
| Metric | 1995 | 1994 |
|---|---|---|
| Total Revenues | $4,937,529 | $4,438,747 |
| Product Sales | $4,350,340 | $3,984,942 |
| Net Profit (Loss) | $29,811 | $(148,266) |
| Research & Development Expenses | $1,578,145 | $1,366,294 |
| Cash and Cash Equivalents | $1,550,011 | $1,295,246 |
| Long-Term Debt | $608,343 | $629,767 |
| Stockholders' Equity | $1,905,316 | $1,875,505 |
| Net Working Capital | $1,849,580 | $1,727,525 |
Margins: Product costs as a percentage of product sales decreased to 45% in 1995 from 49% in 1994. R&D expenses represented 32% of total revenues in 1995.
Material Changes vs. Prior Period
- Profitability: The Company returned to profitability in 1995 with a net profit of $29,811, compared to a net loss of $148,266 in 1994. This was driven by a 9% increase in product sales and improved gross margins.
- Revenue Mix: Grant income increased significantly to $577,189 (12% of total revenue) from $203,805 in 1994, largely due to federal government research grants. Conversely, collaborative R&D revenue dropped to $10,000 from $250,000.
- Product Sales: Sales of FIRST DEFENSE{R} rose to $1.603 million (37% of product sales) from $1.298 million. Sales of the KAMAR HEATMOUNT DETECTOR declined slightly to $2.058 million. Human diagnostic reagent sales grew to $553,000.
- Liquidity: Cash and cash equivalents increased by approximately $255,000 to $1.55 million. Net working capital increased by 7%.
Guidance, Outlook, and Risks
Outlook: Management anticipates that a net operating loss may be incurred in 1996 due to increased investment in R&D. The Company intends to fund this loss from cash reserves and is actively pursuing corporate partners and government grants. Sales of new human products are not expected to begin until 1998 or 1999 pending regulatory approval.
Key Developments:
- CRYPTOGAM{TM}: Phase I/II therapeutic trials showed safety but no significant clinical improvement in symptoms. A Phase I/II prophylactic trial is underway, with a new agreement with Center for Special Immunology, Inc. to conduct further trials.
- TRAVELGAM{TM}: Phase I/II trials completed successfully in June 1995. Further trials planned for 1996.
- Manufacturing: The Company is consolidating operations into its owned facility in March 1996, with expected modification costs of $200,000.
Risks:
- Regulatory: Success depends on obtaining FDA approval for human products, a complex and lengthy process.
- Financial: Heavy reliance on R&D funding; future profitability is contingent on successful commercialization of new products.
- Competition: Competitors include major pharmaceutical firms and other biotech companies with greater resources.
- Product Liability: Inherent risks in manufacturing and marketing health care products.
Investor Verification Checklist
- Grant Sustainability: Verify the status and renewal likelihood of the federal grants that contributed $577,000 to 1995 revenue.
- Clinical Trial Results: Monitor the outcomes of the prophylactic CRYPTOGAM{TM} trials and the Phase III planning for TRAVELGAM{TM}.
- Debt Obligations: Review the terms of the $608,000 long-term debt, including the balloon payment of ~$183,000 due in November 2000 on the mortgage.
- Capital Requirements: Assess the sufficiency of the $1.55 million cash balance to fund the projected 1996 operating loss and the $400,000 in committed capital expenditures (facility modifications and equipment).
- License Agreements: Confirm the status of the exclusive license with Kamar, Inc. (cancelable with 12 months' notice) which generated ~47% of product sales.